Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Selected ESG highlights from Q4
4
ESG
Novartis Biome Sub-Saharan Africa (SSA): Developing innovative / technology-driven solutions in SSA
Refreshed human rights commitment statement: Focusing on 12 human rights areas¹
Disability inclusion: Joined The Valuable 500, supporting a global movement to drive systemic change
Environmental targets on track: -34% Scope 1,2 GHG emissions excluding offsets²; -56% waste
disposal (2025 target: reduce waste disposal by half); engaging top suppliers on 'Green Expectations'
Improved scores for MSCI Controversy, ATMI AMR Benchmark, S&P Global ESG rating³ for 2021
1. In line with United Nations Guiding Principles for Human Rights. 2.2021 GHG Scope 3 will be published in H1 2022. 3. Included in the DJSI World, DJSI Europe
22 Investor Relations | Q4 2021 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation